Find your next M&A target
Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.
Project details
Japanese biopharmaceutical start-up seeks investment
| Project region | Japan |
|---|---|
| Industry | Biomedicine |
| Total value of the target | N/A |
| Expected target net rate of return after deducting all taxes and fees | N/A |
| Validity period of pending order | 365 |
CONTACT ADVISOR
Simon Laube
Assistant Manager, International Business Advisory
| Project highlights | tumor antigen peptide vaccines - good safety and efficacy data |
|---|---|
| Project description |
The Japanese biopharmaceutical start-up is developing tumor antigen peptide vaccines and authorizing immunologic adjuvants. The tumor antigen peptide vaccines are tumor polypeptide antigens (HSP70/GPC3 peptides) which can be combined with three different types of white blood cells (HLA-A2402, HLA-A0201, HLA-A0206). The other component - immunologic adjuvants - have been recognized in clinical trials with good safety and efficacy data; it has already been applied for patent and is planning to conduct Phase 1 and Phase 2 clinical trials. |
Enquire for more information about our services, and how we can help solve challenges for your organization
Contact Us